<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2125">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336761</url>
  </required_header>
  <id_info>
    <org_study_id>2020_21</org_study_id>
    <secondary_id>2020-A00811-38</secondary_id>
    <nct_id>NCT04336761</nct_id>
  </id_info>
  <brief_title>Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France</brief_title>
  <acronym>INCOVPED</acronym>
  <official_title>Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arriving in December 2019, Coronavirus COVID-19 infection is causing a global pandemic with
      high morbidity and mortality among adults and especially seniors. The child appears little or
      no affected by this infection. It is estimated that the child could be asymptomatic or
      pauci-symptomatic carrier and thus be vector of the disease. For this reason, measures have
      been taken to close schools and contain populations in a large number of countries, including
      France. However, there are no data on the prevalence of COVID-19 in children.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of positivity of COVID-19 virus measured by rt-PCR</measure>
    <time_frame>At 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients</measure>
    <time_frame>at the end an average 28 days</time_frame>
    <description>children admitted to pediatric emergencies for respiratory signs
Children hospitalized as a result of travelling to pediatric emergency departments for respiratory signs
Respiratory asymptomatic children admitted to pediatric emergencies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory signs of children tested within 28 day</measure>
    <time_frame>through study completion, an average 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of children hospitalized tested within 28 day</measure>
    <time_frame>through study completion, an average 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contact frequency</measure>
    <time_frame>At inclusion</time_frame>
    <description>the degree of relationship with these contacts and the time spent in contact with them within 24 hours before emergency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of positivity of other respiratory viruses measured by rt-PCR</measure>
    <time_frame>at 28 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">914</enrollment>
  <condition>Coronavirus</condition>
  <condition>COVID</condition>
  <condition>Infection Viral</condition>
  <arm_group>
    <arm_group_label>Child suspected of infection with COVID-19.</arm_group_label>
    <description>Child included with positive included</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>nasopharyngeal swab</intervention_name>
    <description>Data collection and nasopharyngeal swab</description>
    <arm_group_label>Child suspected of infection with COVID-19.</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasopharyngeal swab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children admitted to hospital pediatric emergencies in France during the pandemic period.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1st Line Consultation in Pediatric Emergencies

          -  All reasons for consultation during working hours

          -  Informed and written consent of a parent holder (only 1 authorized companion) and a
             child of understanding age

        Exclusion Criteria:

          -  Refusal of participation by parents/child of decision age

          -  No membership of a social security scheme (beneficiary or entitled)

          -  No understanding of French
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Dubos, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François DUBOS, MD,PhD</last_name>
    <phone>020445982</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.dubos@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Louis MOURIER</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Flora JOANNES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandres, CHU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
    <investigator>
      <last_name>François DUBOS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Mère Enfant CHU</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christèle LE GUEN, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Pédiatriques de Nice CHU-Lenval</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hervé HAAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des enfants - CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Camille BREHIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marie Chinazzo-Vigouroux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric emergencies</keyword>
  <keyword>pandemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

